期刊
GASTROENTEROLOGY
卷 144, 期 6, 页码 1230-1240出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2012.12.042
关键词
Acute Pancreatitis; Chronic Pancreatitis; Pancreatic Ductal Adenocarcinoma
资金
- National Institutes of Health Grant [R01 DK092421, K23 CA148964-01]
- Digestive Disease Center [DK56339]
- Robert Wood Johnson Foundation
- Johns Hopkins School of Medicine Clinical Scientist Award
- National Pancreas Foundation
- Lefkofsky Family Foundation
- NCI SPORE in Gastrointestinal Cancers [P50 CA062924-14]
- Lustgarten Foundation
- Viragh Foundation
- Skip Viragh Pancreatic Cancer Center at Johns Hopkins
- Sol Goldman Pancreatic Cancer Center
- Dana and Albert Cubby Broccoli Endowed Professorship
Immune cells are important in the pathogenesis of acute pancreatitis and determine disease severity. Results from cytokine-based clinical trials for acute pancreatitis have been disappointing, so strategies that target and alter the behavior of infiltrating immune cells require consideration. Recurrent acute pancreatitis can progress to chronic pancreatitis, which is a well-described risk factor for pancreatic ductal adenocarcinoma (PDA). However, most patients with chronic pancreatitis do not develop PDA, and most patients with PDA do not have a history of pancreatitis. Interestingly, chronic pancreatitis and PDA tissues have similarities in their desmoplasia and inflammatory infiltrates, indicating overlapping inflammatory responses. Further studies are needed to determine the differences and similarities of these responses, improve our understanding of PDA pathogenesis, and develop specific immune-based therapies. Immune cells in PDA produce immunosuppressive signals that allow tumors to evade the immune response. Unlike single therapeutic agent studies that block immunosuppressive mechanisms, studies of combination therapies that include therapeutic vaccines have provided promising results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据